FIG. 1A



KRAS:
WT
G12D
G13D
G12C
G13C
X-linked KRAS
KRAS
H/NRAS

FIG. 1B



KRASG12C Inhibitor
(Compound X)
KRASG13C Inhibitor
(Compound B)
KRAS:
WT
G12C
G13C
WT
G12C
G13C
X-linked KRAS
KRAS
H/NRAS
Total
RAS

FIG. 2



Single-dose PK/PD
NCI-H1734 CDX (NSCLC, KRASG13C/WT)
% Tumor DUSP6 mRNA relative to control
Unbound plasma [Compound] (nM)
Compound A 100 mg/kg po
PK: Unbound plasma conc. (nM)
No PD data at 0.5 and 1 hr
100
50
0
10
1
0.1
0.5
1
3
8
24
Time (hr) after dose

FIG. 3




NCI-H1734 CDX (NSCLC, KRASG13C/WT)
Mean Tumor Volume (mm3)
1200
800
400
0
Control
Compound A
Dosing start
Control
Compound A
20
30
40
50
Days Post-implant

FIG. 4


ST2822B PDX (NSCLC, KRASG13C/WT)
Mean Tumor Volume (mm3)
1600
1200
800
400
0
Control
Compound A
Control
Compound A
0
10
20
30
Days on Study